You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our PIK3CA Proteins (PIK3CA)

Full name:
Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide Proteins (PIK3CA)
On www.antibodies-online.com are 3 Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA) Proteins from 2 different suppliers available. Additionally we are shipping PIK3CA Antibodies (145) and PIK3CA Kits (5) and many more products for this protein. A total of 162 PIK3CA products are currently listed.
Synonyms:
6330412C24Rik, C-P3K, caPI3K, CLOVE, CWS5, MCAP, MCM, MCMTC, p110, p110-alpha, p110alpha, pi3-k, PI3-kinase, PI3K, PI3K-alpha
list all proteins Gene Name GeneID UniProt
PIK3CA 18706 P42337
PIK3CA 5290 P42336
Rat PIK3CA PIK3CA 170911  

Show all synonyms

PIK3CA Proteins (PIK3CA) by Origin

Select your origin of interest

More Proteins for PIK3CA Interaction Partners

Mouse (Murine) Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA) interaction partners

  1. Data show that RNA silencing of CCN family member 1 (show CYR61 Proteins) protein (CCN1 (show CCNA2 Proteins)) inhibits retinal neovascularization (RNV) by inhibiting phosphoinositide 3-kinase (PI3K)/AKT protein signaling in mouse pup model of oxyge (show AKT1 Proteins)n-induced retinopathy (OIR).

  2. Reelin (show RELN Proteins) thus plays a role in restraining RAS and PI3-kinase promotion of cell motility and potentially tumour metastasis.

  3. demonstrated that despite having both Kras and Pik3ca mutations at the time of tumor initiation from loss of APC (show APC Proteins)

  4. Chronic CoQ(10) supplementation attenuates aspects of diabetic cardiomyopathy, even in a setting of reduced cardiac PI3K(p110alpha) protective signaling

  5. A subgroup of colon cancers might arise in the setting of activated PI3K, as seen in a PIK3CA mutant mouse model.

  6. p110a as well as p110d Class IA PI3Ks are important to immune regulation; inhibition of both subunits may be an effective therapeutic approach in inflammatory autoimmune diseases like rheumatoid arthritis.

  7. Interestingly, we observed that IRGM1 enhanced F-actin polymerization and triggers epithelial mesenchymal transition (EMT) through a mechanism involved in PIK3CA mediated Rac1 activation.

  8. Study demonstrates the oncogenic cooperation between PI3K and Yap (show YAP1 Proteins) pathways along liver carcinogenesis. The PIK3CA/Yap (show YAP1 Proteins) mouse represents an important preclinical liver tumor model.

  9. Data show that the RNA-binding protein lin28a (show LIN28A Proteins)/microRNA let-7a axis regulated glucose metabolism in part through the insulin (show INS Proteins)-PI3K-mTOR (show FRAP1 Proteins) pathway.

  10. Data show that PI3 kinase is an attractive therapeutic target in malignancies induced by proto-oncogene protein c-Kit mutations.

Human Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA) interaction partners

  1. in a high number of HNSCC tumours, PI3K/Akt (show AKT1 Proteins) signalling is activated by different molecules or by the combination of these molecules.

  2. none of the nine tested SNPs of PIK3CA was associated with susceptibility to oral squamous cell carcinoma in the studied population.

  3. PIK3CA Mutations are associated with Head and Neck Squamous Cell Carcinoma.

  4. Our study demonstrates that the IGF1R (show IGF1R Proteins)/p110b/AKT (show AKT1 Proteins)/mTOR (show FRAP1 Proteins) axis confers resistance to BYL719 in PIK3CA mutant breast cancers

  5. Findings of frequent mutations in CDKN2A, NOTCH1 (show NOTCH1 Proteins), PIK3CA, and EGFR (show EGFR Proteins) (all in excess (show RCC1 Proteins) of 20%) point to potential therapeutic avenues. Trials of targeted therapies directed toward these mutations should be explored.

  6. As depicted in Figure 3, APC (show APC Proteins) (25%) followed by KRAS (20%), TP53 (show TP53 Proteins) (14%), and PIK3CA (11%) were the most frequently mutated genes.

  7. The present study emphasizes that the treatment for breast cancer should include molecular analysis of relevant driver mutations with priority to PIK3CA gene while taking clinical decisions in breast cancer patients.

  8. We describe the case of a patient in whom we were able to confirm a causative PIK3CA mutation.

  9. Data show that the combination of a phosphatidylinositol 3-Kinase (PI3K)/mTOR (show FRAP1 Proteins) protein inhibitor with an androgen receptor {AR (show AR Proteins)) inhibitor results in a synergistic anti-tumor response in non-castration-resistant prostate cancer (CRPC) and CRPC models.

  10. miR (show MLXIP Proteins)-203 represses NF-kappaB (show NFKB1 Proteins) signaling via targeting TAK1 (show MAP3K7 Proteins) and PI3KCA and miR (show MLXIP Proteins)-203 overexpression may contribute to the COPD (show ARCN1 Proteins) initiation.

Cow (Bovine) Phosphoinositide-3-Kinase, Catalytic, alpha Polypeptide (PIK3CA) interaction partners

  1. There are multiple conformations in equilibrium during the course of PI3K SH3 domain unfolding.

  2. PI3K has a role in activation of 5'-AMP (show TMPRSS5 Proteins)-activated kinase during hypoxia-reoxygenation of bovine aortic endothelial cells

  3. Production of PtdIns3P by PI3K-C2alpha (show PIK3C2A Proteins) is required for acquisition of fusion competence in neurosecretion.

  4. crystallographic and biochemical approaches used to gain insight into activating mutations in two noncatalytic p110alpha domains-the adaptor-binding and the helical domains

PIK3CA Protein Profile

Protein Summary

Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers.

Alternative names and synonyms associated with PIK3CA

  • phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)
  • Phosphoinositide-3-kinase, catalytic, alpha polypeptide (GL50803_14855)
  • phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (pik3ca)
  • phosphoinositide-3-kinase, catalytic, alpha polypeptide (LOC100337822)
  • phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca)
  • phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (Pik3ca)
  • phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA)
  • 6330412C24Rik protein
  • C-P3K protein
  • caPI3K protein
  • CLOVE protein
  • CWS5 protein
  • MCAP protein
  • MCM protein
  • MCMTC protein
  • p110 protein
  • p110-alpha protein
  • p110alpha protein
  • pi3-k protein
  • PI3-kinase protein
  • PI3K protein
  • PI3K-alpha protein

Protein level used designations for PIK3CA

phosphoinositide-3-kinase, catalytic, alpha polypeptide , Phosphoinositide-3-kinase, catalytic, alpha polypeptide , PI3-kinase subunit alpha , PI3K-alpha , PI3Kalpha , phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha , phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform , phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha , phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform , phosphoinositide-3-kinase catalytic alpha polypeptide , ptdIns-3-kinase subunit alpha , ptdIns-3-kinase subunit p110-alpha , serine/threonine protein kinase PIK3CA , PI3-kinase p110 subunit alpha , phosphatidylinositol 3-kinase, catalytic, 110-KD, alpha , phosphatidylinositol 3-kinase, catalytic, alpha polypeptide , phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, alpha isoform , PI3K , p110alpha , ptdIns-3-kinase p110 , phosphoinositide 3-kinase catalytic subunit

GENE ID SPECIES
460858 Pan troglodytes
5702156 Giardia lamblia ATCC 50803
100144924 Xenopus (Silurana) tropicalis
100229768 Taeniopygia guttata
100337822 Oryctolagus cuniculus
18706 Mus musculus
5290 Homo sapiens
282306 Bos taurus
170911 Rattus norvegicus
488084 Canis lupus familiaris
424971 Gallus gallus
Selected quality suppliers for PIK3CA Proteins (PIK3CA)
Did you look for something else?